In This SectionTexas Health Research & Education Institute
Disease or Condition
Heart / Atrial Fibrillation
A Long Term Multi-Center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation (Heart/Atrial Fibrillation)
Atrial fibrillation (AF) is an irregular heartbeat that can cause blood clots to form in the heart. These clots can break away and block other blood vessels. If the clot blocks an artery in the brain it can cause a stroke. The chance of a stroke is increased if other diseases or conditions are present including coronary artery disease, high blood pressure, diabetes, heart failure, a previous heart attack or a previous stroke including transient ischemic attacks.
The RE-LY study tested an investigational blood thinning drug, dabigatran etexilate, to see if it would prevent strokes as well as warfarin. This study, RELY-ABLE (an extension study of RE-LY), will test the long-term safety of two dose levels of dabigatran etexilate and will test whether giving customized feedback to subjects and study doctors will improve the health status of the subjects with AF.
Patient must require long-term treatment with oral anticoagulation and investigator determines it is clinically appropriate for patient to continue receiving oral anticoagulation.
Need for anticoagulant treatment for disorders other than atrial fibrillation.
Active infective endocarditis.
Women who are pregnant, lactating or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study.
Patients who have received an investigational drug other than dabigatran in the past 30 days or are participating in another drug study.